

## Video Abstracts

## Abnormal Vertical Eye Movements as a Clue for Diagnosis of Niemann-Pick Type C

Deepak K. Gupta<sup>1</sup>, Victor A. Blanco-Palmero<sup>2</sup>, Wendy K. Chung<sup>3</sup> & Sheng-Han Kuo<sup>1\*</sup>

<sup>1</sup> Department of Neurology, Columbia University, New York, NY, USA, <sup>2</sup> Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain, <sup>3</sup> Departments of Pediatrics and Medicine, Columbia University, New York, NY, USA

## Abstract

**Background:** Adult-onset Niemann–Pick Type C is a rare neurogenetic lysosomal disorder, whose diagnosis is often delayed and missed because of its heterogeneous clinical presentations and rarity as well as the lack of awareness of characteristic eye findings among neurologists.

**Phenomenology Shown:** Impaired smooth pursuits, saccades, and optokinetic nystagmus in the vertical direction, with relatively normal eye movements in the horizontal direction, and ataxia features on finger chase testing, tandem walking, and gait ataxia.

**Educational Value:** Impairment of vertical eye movements in combination with ataxia, cognitive impairment, and/or psychiatric symptoms in an adult patient should always raise clinical suspicion of Niemann–Pick Type C.

Keywords: Niemann–Pick type C, cerebellar ataxia, eye movements

Citation: Gupta DK, Blanco-Palmero VA, Chung WK, Kuo S-H. Abnormal vertical eye movements as a clue for diagnosis of Niemann–Pick type C. Tremor Other Hyperkinet Mov. 2018; 8. doi: 10.7916/D8XS7BGD

\*To whom correspondence should be addressed. E-mail: sk3295@cumc.columbia.edu

Editor: Elan D. Louis, Yale University, USA

Received: March 13, 2018 Accepted: April 4, 2018 Published: May 29, 2018

**Copyright:** © 2018 Gupta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.

Funding: Dr. Kuo has received funding from the National Institutes of Health: NINDS #K08 NS083738 (principal investigator), and the Louis V. Gerstner Jr. Scholar Award, Parkinson's Disease Foundation, and International Essential Tremor Foundation. Dr. Gupta is supported by a Parkinson's Foundation fellowship grant.

Financial Disclosures: None.

**Conflicts of Interest:** The authors report no conflicts of interest.

Ethics Statement: All patients that appear on video have provided written informed consent; authorization for the videotaping and for publication of the videotape was provided.

A 30-year-old male with unremarkable birth history had poor coordination since childhood and below-average school performance. He developed delusions at the age of 21, for which he was treated with bupropion and aripiprazole. At the age of 23, he developed memory difficulty, hand tremor, loss of hand dexterity, and imbalance with occasional falls. He also developed slurred speech at the age of 28. His neurological examination showed impaired smooth pursuit, saccades, and optokinetic nystagmus in the vertical direction with relatively preserved horizontal eye movements (Video 1). The impaired eye movements were even more prominent in the downward direction than the upward direction. He also had cognitive impairment (Montreal Cognitive Assessment score of 19: he lost 2 points in visuospatial/ executive, 2 points in attention, 5 points in delayed recall, and 2 points in orientation), mild dysarthria, and features of cerebellar ataxia.

Routine laboratory testing revealed a reduced platelet count of 122,000 per  $\mu$ L, and an ultrasound showed splenomegaly. A brain magnetic resonance imaging (MRI) scan showed cerebellar atrophy with pontine and medullary atrophy. Targeted genetic testing showed

bi-allelic mutations in the *NPC1* gene: c.3265 G>A, (E1089K) and c.2903 A>G, (N968S); both mutations have been reported in patients with a classical biochemical phenotype of Niemann–Pick type C (NPC).<sup>1,2</sup> No mutations were detected in the *NPC2* gene. Subsequently, his brother, who also reportedly exhibited cognitive symptoms and lack of coordination, was also found to carry these two mutations in *NPC1*.

Impaired vertical eye movements, in combination with cerebellar ataxia, cognitive impairment, and/or psychiatric symptoms, are pathognomonic for NPC.<sup>3</sup> Other considerations for vertical eye movements include progressive supranuclear palsy and Whipple's disease. NPC is a rare lysosomal storage disorder caused by mutations in either *NPC1* (~95% of cases) or *NPC2* (~55% of cases), which lead to abnormal intracellular lipid trafficking and accumulation. NPC most commonly manifests in middle to late childhood after normal development; however, neonatal and adult onset may also occur. In addition to the above-mentioned symptoms, NPC patients may exhibit dystonia, myoclonus, parkinsonism, and gelastic cataplexia, which are not present in our patient.



Video 1. Vertical eye movements and ataxia features in Niemann-Pick Type C. The patient had relatively intact horizontal smooth pursuit, saccades, and optokinetic nystagmus. However, these eye movements in the vertical direction were impaired. In addition, the downward smooth pursuit was slower than the upward smooth pursuit. The patient also exhibited features of cerebellar ataxia as characterized by abnormal finger chase test, tandem walking, and gait ataxia.

Although no curative therapies are currently available for treatment of NPC, early detection is important as patients can be offered treatments with potential disease-modifying agents. These include miglustat,<sup>4</sup> which reduces the synthesis of glycolipids by inhibiting glucosylceramide synthase and possibly slows disease progression, and arimoclomol,<sup>5</sup> which is a co-inducer of heat shock protein and was recently granted rare pediatric disease designation by the US Food and Drug Administration for the treatment of NPC.

## References

I. Mavridou I, Dimitriou E, Vanier MT, Vilageliu L, Grinberg D, Latour P, et al. The Spectrum of Niemann-Pick type C disease in Greece. *JIMD Rep* 2017; 36:41–48. doi: 10.1007/8904\_2016\_41

2. Yang CC, Su YN, Chiou PC, Fietz MJ, Yu CL, Hwu WL, et al. Six novel NPC1 mutations in Chinese patients with Niemann-Pick disease type C. *J Neurol Neurosurg Psychiatry* 2005;76:592–595. doi: 10.1136/jnnp.2004. 046045

**3.** Patterson MC, Clayton P, Gissen P, Anheim M, Bauer P, Bonnot O, et al. Recommendations for the detection and diagnosis of Niemann-Pick disease type C. An update. *Neurol Clin Pract* 2017;7:499–511. doi: 10.1212/CPJ. 000000000000399

4. Lyseng-Williamson KA. Miglustat: a review of its use in Niemann-Pick disease type C. *Drugs* 2014;74:61–74. doi: 10.1007/s40265-013-0164-6

**5.** Kirkegaard T, Gray J, Priestman DA, Wallom KL, Atkins J, Olsen OD, et al. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. *Sci Transl Med* 2016;8:355ra118. doi: 10.1126/scitranslmed. aad9823